MK-1029

DRUG3 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

Asthma

Phase 1

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-1029 in Participants With Mild to Moderate Asthma

CompletedNCT01370317

Merck Sharp & Dohme LLCAsthma

Start: 2011-06-01End: 2011-12-27Updated: 2019-01-25

Phase 2

Study to Evaluate the Effectiveness and Safety of MK-1029 in the Treatment of Persistent Asthma That is Not Controlled With Montelukast (ML) in Adults (MK-1029-011)

CompletedNCT01624974

Merck Sharp & Dohme LLCAsthma

Start: 2012-08-09End: 2014-05-05Updated: 2019-01-02

A Dose-Ranging Study of MK-1029 in Adults With Persistent Asthma (MK-1029-012)

TerminatedNCT01656395

Merck Sharp & Dohme LLCAsthma

Start: 2012-08-23End: 2014-07-08Updated: 2018-09-13